View Financial Health2invest 배당 및 자사주 매입배당 기준 점검 0/62invest 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률3.7%자사주 매입 수익률총 주주 수익률3.7%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Apr 212invest AG, Annual General Meeting, May 27, 20262invest AG, Annual General Meeting, May 27, 2026, at 12:00 W. Europe Standard Time.New Risk • Apr 16New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 95% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (95% accrual ratio). Minor Risk Market cap is less than US$100m (€69.6m market cap, or US$79.2m).공고 • Mar 042invest AG, Annual General Meeting, Apr 11, 20252invest AG, Annual General Meeting, Apr 11, 2025, at 15:00 W. Europe Standard Time.New Risk • Feb 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€69.6m market cap, or US$72.7m).공고 • May 082invest AG, Annual General Meeting, Jun 12, 20242invest AG, Annual General Meeting, Jun 12, 2024, at 11:00 W. Europe Standard Time.분석 기사 • May 01We Think 2invest's (ETR:2INV) Robust Earnings Are ConservativeEven though 2invest AG's ( ETR:2INV ) recent earnings release was robust, the market didn't seem to notice. Our...New Risk • Mar 04New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (€2.4m revenue, or US$2.7m). Market cap is less than US$100m (€45.4m market cap, or US$49.2m).New Risk • Jun 30New major risk - Revenue and earnings growthEarnings have declined by 6.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.6% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€36.5m market cap, or US$39.7m).공고 • Apr 152invest AG to Report Fiscal Year 2021 Results on Apr 19, 20222invest AG announced that they will report fiscal year 2021 results on Apr 19, 2022Is New 90 Day High Low • Mar 15New 90-day low: €11.52The company is down 30% from a price of €16.43 on 15 December 2020. Underperformed the German market, which is up 10.0% over the last 90 days. Lagged the Biotechs industry, which is down 3.0% over the same period.Is New 90 Day High Low • Feb 22New 90-day low: €1.40The company is down 23% from its price of €1.82 on 24 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.Is New 90 Day High Low • Feb 04New 90-day low: €1.60The company is down 19% from its price of €1.98 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period.공고 • Dec 314basebio AG Announces Board Changes4basebio AG announced that agreed that the two members of the Management Board, Dr. Heikki Lanckriet and Mr. David Roth, will each resign from the Management Board of 4basebio AG with effect from December 30, 2020. Dr. Heikki Lanckriet and Mr. David Roth will focus on managing the operational business in the field of genomics and DNA manufacturing of 4basebio SE, whose spin-off from 4basebio AG and registration in the UK have already taken place. It is planned to admit the shares of 4basebio SE to trading on the Alternative Investment Market (AIM), a market segment of the London Stock Exchange, in January 2021. The Supervisory Board would like to thank Dr. Heikki Lanckriet and Mr. David Roth for their many years of service to 4basebio AG. The remaining member of the Executive Board of 4basebio AG, Mr. Hansjörg Plaggemars, will take over their areas of responsibility and will in future be responsible for the allocation of liquid funds to suitable investment opportunities within the biotech sector and in other areas.공고 • Dec 104basebio AG (XTRA:4BSB) completed the spin-off of Genomics and DNA manufacturing business.The Board of Directors of 4basebio AG (XTRA:4BSB) announced the spin-off of unknown majority stake in Genomics and DNA manufacturing business on August 17, 2020. A spin-off of Genomics and DNA manufacturing business into a separate company is intended which shall have its corporate seat in the UK and be listed on the Alternative Investment Market. 4basebio AG is considering retaining a significant minority stake in the new entity and distributing the remaining shares to its existing shareholders. As part of this process, 4basebio AG will ensure the spin-off is suitably capitalized from the existing cash of 4basebio AG. The management board of 4basebio AG would join the Board of the spin-off and assume responsibility for the day to day operation of this organization. As a result of the planed process, 4basebio AG would in addition to its participation in the new company still hold a significant cash position. The deal is subject to an ongoing legal and tax review. On November 3, 2020, the shareholders of 4basebio AG approved the transaction. The intention is to complete this core process by December 31, 2020. 4basebio AG (XTRA:4BSB) completed the spin-off of Genomics and DNA manufacturing business on December 8, 2020.공고 • Dec 024basebio AG Announces Board Changes4basebio AG announced that the previous member of the company's Supervisory Board, Mr. Hansjörg Plaggemars, resigned from his office as a member of the company's Supervisory Board by letter dated 29 November 2020. Mr. Alexander Link, who was elected as a substitute member of the Supervisory Board during the Extraordinary General Meeting of the Company on 3 November 2020, thus automatically takes over the Supervisory Board mandate from Mr. Plaggemars. In addition, the Supervisory Board appointed Hansjörg Plaggemars to the Executive Management Board of 4basebio AG at its meeting. Mr. Plaggemars will become the third member of the Executive Management Board alongside Dr Heikki Lanckriet and David Roth.Is New 90 Day High Low • Oct 22New 90-day low: €1.95The company is down 8.0% from its price of €2.12 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 15% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 2INV 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 2INV 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장2invest 배당 수익률 vs 시장2INV의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (2INV)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.7%업계 평균 (Biotechs)2.3%분석가 예측 (2INV) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 2INV 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 2INV 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 2INV 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 2INV 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/04/05 09:17종가2026/01/06 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스2invest AG는 4명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Andrew Murray DarleyCavendishMark BrewerCavendishChristian OrqueraFirst Berlin Equity Research GmbH1명의 분석가 더 보기
공고 • Apr 212invest AG, Annual General Meeting, May 27, 20262invest AG, Annual General Meeting, May 27, 2026, at 12:00 W. Europe Standard Time.
New Risk • Apr 16New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 95% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (95% accrual ratio). Minor Risk Market cap is less than US$100m (€69.6m market cap, or US$79.2m).
공고 • Mar 042invest AG, Annual General Meeting, Apr 11, 20252invest AG, Annual General Meeting, Apr 11, 2025, at 15:00 W. Europe Standard Time.
New Risk • Feb 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€69.6m market cap, or US$72.7m).
공고 • May 082invest AG, Annual General Meeting, Jun 12, 20242invest AG, Annual General Meeting, Jun 12, 2024, at 11:00 W. Europe Standard Time.
분석 기사 • May 01We Think 2invest's (ETR:2INV) Robust Earnings Are ConservativeEven though 2invest AG's ( ETR:2INV ) recent earnings release was robust, the market didn't seem to notice. Our...
New Risk • Mar 04New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (€2.4m revenue, or US$2.7m). Market cap is less than US$100m (€45.4m market cap, or US$49.2m).
New Risk • Jun 30New major risk - Revenue and earnings growthEarnings have declined by 6.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.6% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€36.5m market cap, or US$39.7m).
공고 • Apr 152invest AG to Report Fiscal Year 2021 Results on Apr 19, 20222invest AG announced that they will report fiscal year 2021 results on Apr 19, 2022
Is New 90 Day High Low • Mar 15New 90-day low: €11.52The company is down 30% from a price of €16.43 on 15 December 2020. Underperformed the German market, which is up 10.0% over the last 90 days. Lagged the Biotechs industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Feb 22New 90-day low: €1.40The company is down 23% from its price of €1.82 on 24 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Feb 04New 90-day low: €1.60The company is down 19% from its price of €1.98 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period.
공고 • Dec 314basebio AG Announces Board Changes4basebio AG announced that agreed that the two members of the Management Board, Dr. Heikki Lanckriet and Mr. David Roth, will each resign from the Management Board of 4basebio AG with effect from December 30, 2020. Dr. Heikki Lanckriet and Mr. David Roth will focus on managing the operational business in the field of genomics and DNA manufacturing of 4basebio SE, whose spin-off from 4basebio AG and registration in the UK have already taken place. It is planned to admit the shares of 4basebio SE to trading on the Alternative Investment Market (AIM), a market segment of the London Stock Exchange, in January 2021. The Supervisory Board would like to thank Dr. Heikki Lanckriet and Mr. David Roth for their many years of service to 4basebio AG. The remaining member of the Executive Board of 4basebio AG, Mr. Hansjörg Plaggemars, will take over their areas of responsibility and will in future be responsible for the allocation of liquid funds to suitable investment opportunities within the biotech sector and in other areas.
공고 • Dec 104basebio AG (XTRA:4BSB) completed the spin-off of Genomics and DNA manufacturing business.The Board of Directors of 4basebio AG (XTRA:4BSB) announced the spin-off of unknown majority stake in Genomics and DNA manufacturing business on August 17, 2020. A spin-off of Genomics and DNA manufacturing business into a separate company is intended which shall have its corporate seat in the UK and be listed on the Alternative Investment Market. 4basebio AG is considering retaining a significant minority stake in the new entity and distributing the remaining shares to its existing shareholders. As part of this process, 4basebio AG will ensure the spin-off is suitably capitalized from the existing cash of 4basebio AG. The management board of 4basebio AG would join the Board of the spin-off and assume responsibility for the day to day operation of this organization. As a result of the planed process, 4basebio AG would in addition to its participation in the new company still hold a significant cash position. The deal is subject to an ongoing legal and tax review. On November 3, 2020, the shareholders of 4basebio AG approved the transaction. The intention is to complete this core process by December 31, 2020. 4basebio AG (XTRA:4BSB) completed the spin-off of Genomics and DNA manufacturing business on December 8, 2020.
공고 • Dec 024basebio AG Announces Board Changes4basebio AG announced that the previous member of the company's Supervisory Board, Mr. Hansjörg Plaggemars, resigned from his office as a member of the company's Supervisory Board by letter dated 29 November 2020. Mr. Alexander Link, who was elected as a substitute member of the Supervisory Board during the Extraordinary General Meeting of the Company on 3 November 2020, thus automatically takes over the Supervisory Board mandate from Mr. Plaggemars. In addition, the Supervisory Board appointed Hansjörg Plaggemars to the Executive Management Board of 4basebio AG at its meeting. Mr. Plaggemars will become the third member of the Executive Management Board alongside Dr Heikki Lanckriet and David Roth.
Is New 90 Day High Low • Oct 22New 90-day low: €1.95The company is down 8.0% from its price of €2.12 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 15% over the same period.